Haemonetics Corporation
Haemonetics Corporation (HAE) Revenue
Annual & quarterly revenue history · segment & region breakdown
HAE · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsHaemonetics Corporation trailing twelve-month (TTM) revenue is $1.33B, a decrease of 1.97% year-over-year from $1.33B in FY2026.
Revenue trend
2026 – 2007 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2026-03-28 | $1.33B | -$0.03B | -1.97% |
| 2025-03-29 | $1.36B | +$0.05B | +3.95% |
| 2024-03-31 | $1.31B | +$0.14B | +12.01% |
| 2023-03-31 | $1.17B | +$0.18B | +17.67% |
| 2022-03-31 | $0.99B | +$0.12B | +14.10% |
| 2021-03-31 | $0.87B | -$0.12B | -11.94% |
| 2020-03-31 | $0.99B | +$0.02B | +2.16% |
| 2019-03-31 | $0.97B | +$0.06B | +7.04% |
| 2018-03-31 | $0.90B | +$0.02B | +2.01% |
| 2017-03-31 | $0.89B | -$0.02B | -2.50% |
Compare revenue vs peers
Medical - Instruments & SuppliesCompare HAE revenue against listed peers. Click any row to open that company's revenue tab.
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Haemonetics Corporation receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Haemonetics Corporation reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Haemonetics Corporation's 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
HAE revenue · 4 questionsHAE's trailing twelve-month (TTM) revenue is $1.33B. That is a decrease of 1.97% year-over-year from $1.33B in FY2026.
▸ Source: FMP · Haemonetics Corporation SEC filings · GAAP · Haemonetics Corporation SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026